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the two systems, the two parameters, therefore, should both be consid-
ered during decision-making for therapeutic approaches.
PD6-2-8 Mesothelioman and Other Thoracic Malignancy, Mon, 16:00 - 17:30
High-resolution ROMA analysis of chromosomal rearrangements 
in mesothelioma patients with poor and good survival
Ivanov, Sergey V.1 Ivanova, Alla V.1 Lucito, Robert2 Pass, Harvey I.13 
1 NYU School of Medicine, New York, NY, USA 2 Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY, USA 3 NCI Cancer Center, New 
York, NY, USA 
Background: Representational oligonucleotide microarray analysis 
(ROMA) is a recently developed microarray-based high-resolution 
technology that helps linking chromosomal losses and gains with 
speciﬁc genetic events. ROMA identiﬁes the boundaries of deletions, 
duplications, and ampliﬁcations with the accuracy of roughly 50-100 
kb throughout the whole human genome. Mesothelioma is an aggres-
sive asbestos-related cancer with short (median 11-22 months) survival 
and poorly investigated genetic components. 
Methods: We performed ROMA on DNAs isolated from mesothelioma 
patients to assess the possible link between chromosome rearrange-
ments and prognosis and to identify the critical chromosomal events 
involved in the disease progression. Analysis of the signal intensity 
data obtained with microarray that contained more than 40,000 features 
was performed using CGH-Explorer software. 
Results: A remarkably high rate of losses and gains on the sub-chro-
mosomal level was reported in the patients with poor survival. The 
most frequent events in the long survivors were losses of chromosomes 
1, 4p, 6q, 9, 10, 14-22 and gains of chromosomes 12 and 13. The 
comparison between two groups of patients helped to identify “early” 
chromosomal events and genes that may play critical roles in mesothe-
lioma progression. 
PD6-3-1 Supportive Care & QOL, Mon, 16:00 - 17:30
Health related quality of life, mood disorders and coping abilities 
in an unselected sample of patients with primary lung cancer.
Rolke, Heidi B.1 Bakke, Per S.2 Gallefoss, Frode1 
1 Dept. of Pulmonology, Sorlandet Hospital, Kristiansand S, Norway 2 
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Background: Health related quality of life (HRQoL) and mood disor-
ders have previously been evaluated only in selected patients with pri-
mary lung cancer, for example alongside chemotherapy studies or after 
lung surgery. The aims of this study were therefore to assess HRQoL 
and mood disorders, as well as coping abilities, in an unselected sample 
of patients with primary lung cancer, and test the associations between 
them and performance status (Eastern Cooperative Oncology Group, 
ECOG).
Methods: A questionnaire-based prospective study of all patients diag-
nosed with primary lung cancer in Southern Norway from June 14th, 
2002 to June 13th, 2005. HRQoL was assessed according to European 
Organization for Research and Treatment of Cancer (EORTC) Quality 
of Life Questionnaires (QLQ C30 and LC13 (the lung speciﬁc module); 
for both, a high symptom or function score indicates a low or high 
HRQoL, respectively), anxiety and depression according to Hospital 
Anxiety and Depression scale (HAD) and coping ability according to 
Sense of Coherence 13 (SoC) (13 indicating lowest coping ability and 
91 the highest).
Results: According to EORTC the function scores for global QoL, role 
and cognitive varied between 49,4 (mean, SDplusmn26), 41,1 (38) and 
77,3 (27). Correspondingly, symptom scores ranged from 52,7 (31) 
for fatigue, dyspnoea 52,3 (34) to haemoptysis 6,7 (18). There were 
no differences between NSCLC and SCLC except for fatigue and sore 
mouth, being more pronounced in SCLC 60,6, (31) than in NSCLC 
50,7 (35) and 7,6 (21) versus 15,6 (31), respectively (p’s<0,05). These 
scores are poorer than recorded in EORTC databases from chemothera-
py and radiotherapy studies.
According to HAD, 17% of patients scored compatible with anxi-
ety and 14% with depression. Seven percent scored consistent with 
combined anxiety and depression. Mean SoC score was 58,3 (SD 7). A 
HAD-score compatible with anxiety or depression was associated with 
signiﬁcantly poorer HRQoL scores. The Odds Ratio for depression was 
4 in cases of poor performance status (ECOG) 3-4 compared to ECOG 
0-2. A reduced coping ability was associated with anxiety (p=0,025, 
95%CI 0,39 - 5,70) and depression (p=0,035, 95%CI 0,24 - 6,60). 
Conclusion: In this survey on unselected patients with newly diag-
nosed lung cancer, mean HRQoL scores were poorer than reference 
values from previous, treatment-based studies. Patients with HAD 
scores compatible with depression and/or anxiety, percept more 
symptoms and report reduced quality of life at the time of diagnosis 
compared with patients without mood-related disorders. Anxiety and 
depression are also associated with lower coping abilities.
PD6-3-2 Supportive Care & QOL, Mon, 16:00 - 17:30
Research priorities in non-small-cell lung cancer (NSCLC): 
recommendations of the Scientific Leadership Council (SLC) 
in Lung Cancer of the Coalition of Cancer Cooperative Groups 
(CCCG)
Schiller, Joan H. 
UT Southwestern Medical Center, Dallas, TX, USA
Background: While many potentially revolutionary therapies are being 
developed for NSCLC, the leading cause of cancer-related death in 
the US, advances are being made in screening and staging technology. 
Focused, consensus-based recommendations of research priorities, em-
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phasizing which clinical trials need to be conducted within the next 3 
years to reduce NSCLC-related morbidity/mortality, would be of value.
Methods: The SLC in Lung Cancer, an initiative of the CCCG to 
establish and advance national clinical research priorities in lung can-
cer, is a multidisciplinary group with representation from cooperative 
groups, Specialized Programs of Research Excellence, cancer centers, 
and leading academic and community institutions. The initial meeting 
of the SLC in Lung Cancer was held in Philadelphia, Pennsylvania, 
on November 13-14, 2005, followed by a scientiﬁc dialogue with as-
sociated constituencies (patient advocacy groups and pharmaceutical 
companies engaged in lung cancer drug development) in Santa Monica, 
California on January 25-26, 2006. This report summarizes the primary 
research priorities identiﬁed during this series of meetings.
Results: Eight primary research priorities were identiﬁed:
Clinical trial design/accrual
• Identify and address barriers to accrual into adjuvant trials, building 
awareness among patients and clinicians
• Evaluate new measures of response
• Support novel agent development and associated biomarker valida-
tion
• Revisit trial design approach for novel agents with consideration of 
traditionally low accrual rates in early-stage NSCLC
• Ensure adequate funding of trials and correlative studies
Screening and staging
• Integrate emerging CT scan data into screening paradigms
• Prospectively evaluate molecular screening tests
• Develop new molecular imaging and staging approaches
Conclusions: The SLC in Lung Cancer has identiﬁed several priority 
research areas to be addressed in the next 3-5 years, which will guide 
continued CCCG for advancing NSCLC research. The recommenda-
tions rely on adequate clinical trial accrual and ongoing cooperative 
group support.
PD6-3-3 Supportive Care & QOL, Mon, 16:00 - 17:30
Medical and economical impact of bone metastases in lung cancer 
patients: a prospective French national, multicentric study (GFPC 
06-01 study)
Decroisette, Chantal1 Monnet, Isabelle2 Bota, Suzanna3 Bigay-Game, 
Laurence4 Le Caer, Herve5 Berard, Henri6 David, Philippe7 Audigier-
Valette, Clarisse8 Geriniere, Laurence9 Chouaid, Christos10 
1 CHU Limoges, Limoges, France 2 CHIC Creteil, Creteil, France 3 
CHU Rouen, Rouen, France 4 CHU Toulouse, Toulouse, France 5 CH 
Draguignan, Draguignan, France 6 HIA Toulon, Toulon, France 7 CH 
ELBEUF, Elbeuf, France 8 CHI Toulon, Toulon, France 9 CH Lyon, 
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Background: Bone metastases are an important emerging problem in 
patients with lung cancer and are leading to increasing consumption of 
health care resources. 
Objectives: To assess the epidemiology, the management strategies and 
the costs of bone metastases in lung cancer; to model the management 
of these patients by a Markov model in order to evaluate the effective-
ness of different therapeutic strategies.
Methods: prospective, national, multicentric, observational, epide-
miological study planned to include 500 patients between may 2006 
and may 2007, with a one year follow up, a monthly report of skeletal-
related events and resources consumptions. The economic analysis is 
limited to the direct costs with the health care payer’s perspective.
Results: At this time, 404 patients are included by 36 centres: men: 
77,2%, median age: 61 (39-84) years, non small cell lung cancer: 90%. 
Bone diagnosis metastases is made by scintigraphy (59.7%), standard 
radiology or RMI (3.4%), and bone-scan (36.9%). At inclusion the 
median number of lesions was 4; 74.4% of patients receive an analgesic 
treatment, 41.5% a biphosphonates therapy (zoledronate in 83% of 
cases), 20.5% a radiotherapy and 5%.had a bone-surgery. 
Conclusion: complete demographic, clinical and economical datas will 
be presented at the IASCL meeting.
Supported by a grant from Amgen and Novartis Pharmaceuticals.
PD6-3-4 Supportive Care & QOL, Mon, 16:00 - 17:30
Responding to the needs and quality of life experiences of advanced 
non small cell lung cancer patients
Lewis, Craig1 Treloar, Carla2 
1 Department of Medical Oncology, Prince of Wales Hospital, Rand-
wick, NSW, Australia 2 National Centre in HIV Social Research, Univer-
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Background: Little is known about the patient’s and carer’s experience 
of non small cell lung cancer (NSCLC), despite a growing research in-
terest in quality of life, psychosocial aspects and unmet needs of cancer 
patients. The aim of this project is to explore and describe the NSCLC 
patient and carer perspective in terms of their needs (including unmet 
needs) and quality of life issues. 
Method: Focus groups were conducted with 27 patients with Stage 
IIIB/IV NSCLC recruited from seven hospitals in New South Wales 
and Queensland including public and private, metropolitan and regional 
with visiting oncology services. Focus groups with 13 carers were 
conducted in three sites. A semi-structured discussion guide was used. 
Participants were asked to discuss the needs of people with NSCLC, 
impact on families, concerns about the future, interactions with health 
care providers, experiences and expectations of patient support groups. 
Discussions were audio-taped and transcribed verbatim. 
Results: Overall, participants described high satisfaction with the 
quality of health and supportive care received. However, there was a 
range of experiences relating to the degree of engagement in “driv-
ing” or “managing” their health care: some participants were satisﬁed 
with being directed through treatment, others wanted to be “one step 
ahead” of treatment delivery. One patient was particularly fearful of his 
condition and unconnected with any support service. Patient partici-
pants expressed concerns regarding the impact of NSCLC on their 
families and, in particular, their spouses. Patients described difﬁculties 
in communicating with their spouses in discussing their thoughts, fears 
and concerns about the future. Issues discussed also included need-
ing to know “how they would die”, lack of choice regarding voluntary 
euthanasia and, for younger participants, communicating and dealing 
with the reactions of their young children. Typically, carers seemed 
to “hide” their feelings about the cancer and the impact on their lives. 
They also described putting the rest of their lives “on hold” to care for 
their partners. The lack of media attention on NSCLC (or prominence 
of adverse media around smoking and lung cancer) was a concern for 
some participants and affected the extent and quality of support they 
received from family and social networks. 
